Simcha Therapeutics
About
Leadership
Board of Directors
Scientific Advisors
Investors
Science
Overview
Pipeline
Publications
Patients
Culture & Careers
Partnering
News
Press Releases
Media
Contact
Decoy-resistant IL-18 for relapse or preemptive treatment of MRD+ AML and MDS after allogeneic HSCT
MENU
About
Leadership
Board of Directors
Scientific Advisors
Investors
Science
Overview
Pipeline
Publications
Patients
Culture & Careers
Partnering
News
Press Releases
Media
Contact